 |
1 Company | 1 Product |
|
|
1 Product | |
2 Diseases | |
1 Trial |  |
8 News |  |
| «12...89101112131415161718...3233» |
- | Journal: Ginsenoside Rd protects transgenic Caenorhabditis elegans from β-amyloid toxicity by activating oxidative resistant. (Pubmed Central) - Jan 3, 2023
Additional research with transgenic worms showed that GS-Rd aided in the movement of DAF-16 from the cytoplasm to the nucleus. Taken together, the results indicate that GS-Rd significantly reduces Aβ aggregation by targeting the MAPK signal pathway, induces nuclear translocation of DAF-16 to activate downstream signaling pathways and increases resistance to oxidative stress in C. elegans to protect against Aβ-induced toxicity.
- || Aduhelm (aducanumab) / Eisai, Biogen, lecanemab (BAN2401) / Biogen, BioArctic, Eisai, donanemab (LY3002813) / Eli Lilly
Review, Journal: Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease:insights from clinical trials with secretase inhibitors and monoclonal antibodies. (Pubmed Central) - Jan 1, 2023
We found that β-secretase and γ-secretase inhibitors produce detrimental cognitive effects by significantly reducing CSF Aβ levels. We speculate that monoclonal antibodies targeting Aβ protofibrils, fibrils or plaques may improve cognitive performance in early AD by increasing soluble Aβ levels through Aβ aggregate disassembly and/or stabilization of existing Aβ monomers.These findings suggest that the real culprit in AD may be decreased levels of soluble monomeric Aβ due to sequestration into brain Aβ aggregates and plaques.
- | Preclinical, Journal: Study on multi-target effects of PIMPC on Aβ/Cu-induced Alzheimer's disease model of rats. (Pubmed Central) - Jan 1, 2023
In addition, PIMPC may play an anti-apoptotic effect by down-regulating the high expression of cleaved Caspase-3 protein, and it can modulate ATPase and nitric oxide synthase (NOS) levels, oxidative stress and neurotransmitter disturbance. In summary, PIMPC acts on multiple targets to relieve the learning and memory impairment of AD rats induced by Aβ/Cu.
- | Journal: Atrial Natriuretic Peptide Associated with Cardiovascular Diseases Inhibits Amyloid-β Aggregation via Cross-Seeding. (Pubmed Central) - Dec 29, 2022
Finally, using transgenic C. elegans worms that express the human muscle-specific Aβ, ANP can also effectively delay Aβ-induced worm paralysis, decrease Aβ plaques in worm brains, and reduce reactive oxygen species (ROS) production, confirming its in vivo inhibition ability to prevent neurodevelopmental toxicity in worms. This work discovers not only a new cross-seeding system between the two disease-related proteins but also a new finding that ANP possesses a new biological function as an Aβ inhibitor in the nonaggregated state.
- | Journal: A Kinetic Map of the Influence of Biomimetic Lipid Model Membranes on Aβ Aggregation. (Pubmed Central) - Dec 28, 2022
By using large unilamellar vesicles to model cellular membranes at different locations, including the inner and outer leaflets of the plasma membrane, late endosomes, the ER, and the Golgi apparatus, we show that Aβ aggregation is inhibited by the ER and Golgi model membranes. These results provide a preliminary map of the possible effects of the membrane composition in different cellular locations on Aβ aggregation and suggest the presence of an evolutionary optimization of the lipid composition to prevent the intracellular aggregation of Aβ.
- || Review, Journal: The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer's disease: a literature review. (Pubmed Central) - Dec 28, 2022
Methodologies that quantitate Aβ42 and 40 peptides in blood via immunoassay or immunoprecipitation-mass spectrometry (IP-MS) were considered, and their ability to distinguish participants with amyloidosis compared to amyloid PET and CSF Aβ measures as reference standards was evaluated. Recent studies indicate that some IP-MS assays perform well in accurately and precisely measuring Aβ and detecting brain amyloid aggregates.
- | Journal: Computational screening for new neuroprotective ingredients against Alzheimer's disease from bilberry by cheminformatics approaches. (Pubmed Central) - Dec 27, 2022
Moreover, Ma-3-gal-Cl could inhibit the Aβ aggregation via binding with Aβ monomer and fibers. Thus, Ma-3-gal-Cl showed significant effects on protecting SH-SY5Y cells from Aβ/Cu/AA induced damage via antioxidation effect and inhibition effect to the Aβ aggregation.
- | Preclinical, Journal: Effects of electroacupuncture on the expression of β-amyloid and autophagy-related proteins in hippocampal cells of mice with Alzheimer's disease (Pubmed Central) - Dec 27, 2022
Thus, Ma-3-gal-Cl showed significant effects on protecting SH-SY5Y cells from Aβ/Cu/AA induced damage via antioxidation effect and inhibition effect to the Aβ aggregation. EA can reduce the expression levels of autophagy-related proteins LC3 and p62 in APP/PS1 transgenic mice, improve the hip-pocampal autophagy state, reduce intracellular Aβ aggregation, and thus improve the learning and memory ability.
- || Review, Journal: Oligomer Formation by Amyloid-β42 in a Membrane-Mimicking Environment in Alzheimer's Disease. (Pubmed Central) - Dec 24, 2022
The low levels and heterogeneity of Aβ oligomers have made the determination of their structures difficult, but recent structure determinations of oligomers either formed or initiated in detergents have been achieved. We report here on the structures of these oligomers and suggest how they may be involved in AD.
- | Preclinical, Journal: Lysine-targeting inhibition of amyloid β oligomerization by a green perilla-derived metastable chalcone in vitro and in vivo. (Pubmed Central) - Dec 23, 2022
Of note, in two AD mouse models using immunoaffinity purification-mass spectrometry, adduct formation between dDDC and brain Aβ was observed in a similar manner as reported in vitro. The present findings unraveled the lysine-targeting inhibitory mechanism of metastable dietary ingredients regarding Aβ oligomerization.
- | Journal: Ambient Benzo[a]pyrene's Effect on Kinetic Modulation of Amyloid Beta Peptide Aggregation: A Tentative Association between Ultrafine Particulate Matter and Alzheimer's Disease. (Pubmed Central) - Dec 23, 2022
In contrast, 12.5 mM and 50.0 mM of B[a]P decreased interpeptide interactions and H-bonding due to the aggregation of numerous B[a]P clusters with the peptides, suppressing oligomerization kinetics of Aβ peptides by 13% and 167%, respectively. While the study elucidates the effect of small environmental hydrophobic molecules on the formation of Aβ oligomers, the impact of ambient ultrafine particles on AD in the complex composition of the environmental realm requires further systematic delving into the field.
- | Preclinical, Journal: Low-dose brain irradiation normalizes TSPO and CLUSTERIN levels and promotes the non-amyloidogenic pathway in pre-symptomatic TgF344-AD rats. (Pubmed Central) - Dec 23, 2022
Interestingly, we showed for the first time that sAPPα levels were improved by the treatment, showing a higher activation of the non-amyloidogenic pathway, that could favor neuronal survival. The current evidence confirms the capacity of LD-RT to successfully modulate two pathological hallmarks of AD, namely amyloid and neuroinflammation, when applied before symptoms onset.
- hyoscine butylbromide oral / Generic mfg.
NOVEL MOLECULAR HYBRIDS OF 5-PHENYL-1,3,4-OXADIAZOLE AND 2-PYRIDYLPIPERAZINE AS POTENTIAL MULTITARGETED AGENTS TO TREAT ALZHEIMER'S DISEASE (EXHIBITION) - Dec 23, 2022 - Abstract #ADPD2023ADPD_1808;
Compound 1a has shown excellent actvi ty against multiple targets and improved the learning and memory signficantly (p < 0.001) against scopolamine - and A? -induced cognitive dysfunctions on Y -maze and Morris water maze.
- dobutamine / Generic mfg., atenolol / Generic mfg.
REPURPOSING ADRENORECEPTOR DRUGS FOR ALZHEIMER'S DISEASE? (EXHIBITION) - Dec 23, 2022 - Abstract #ADPD2023ADPD_1781;
aggregation making them p otential multi target drug ligands. More studies are needed to fully understand the potential protective role of these receptors in AD.
- THE PTAU INTERACTOME IN SPORADIC ALZHEIMER'S DISEASE ACROSS APOE GENOTYPES (EXHIBITION) - Dec 23, 2022 - Abstract #ADPD2023ADPD_1777;
More studies are needed to fully understand the potential protective role of these receptors in AD. Our proteomic results will be validated in the human brain by histological and biochemical studies, paving the way to the identification of new therapeutic targets for AD.
- CYTOSKELETAL PROTEINS ARE NOVEL BINDING PARTNERS OF BRI2-BRICHOS DOMAIN (EXHIBITION) - Dec 23, 2022 - Abstract #ADPD2023ADPD_1417;
We identified cytoskeletal proteins includin g spectrin, drebrin and tubulin as novel Bri2 -BRICHOS biding proteins. Further understanding of Bri2 -BRICHOS function in relation to the cytoskeleton may help evaluation of rh Bri2 - BRICHOS as an AD therapy.
- PEPTOIDS AS POTENTIAL MODULATORS TO REDUCE S100B-INDUCED RAGE-ASSOCIATED INFLAMMATION IN ALZHEIMER'S DISEASE (EXHIBITION) - Dec 23, 2022 - Abstract #ADPD2023ADPD_1391;
These results implicate peptoids as a potential therapeutic agent for not only AD but also for other inflammation -related illnesses. Because the se peptoids have also exhibited the ability to modulate beta -amyloid aggregation and transform the morphology of the aggregates formed, they may function as dual -target therapeutics for AD.
- NEUROTOXIC A?42 OLIGOMERS CAN BE SELECTIVELY DETECTED AND NEUTRALIZED BY SINGLE DOMAIN ANTIBODIES (EXHIBITION) - Dec 23, 2022 - Abstract #ADPD2023ADPD_1364;
All these data provide a solid foundation for the development of sdAbs -based immunodiagnostic tools that can selectively detect aggregate conformations in complex mixtures such as biological samples for an early differential diagnosis of AD. Furthermore, our study contributes to the generation of novel therapeutic approaches for AD and other neurodegenerative disorders.
- SAFE AND NEUROPROTECTIVE EFFECTS OF A SYNTHETIC COUMARIN DERIVATIVE ZN014 FOR EARLYPHASE ALZHEIMER'S DISEASE (EXHIBITION) - Dec 23, 2022 - Abstract #ADPD2023ADPD_1356;
Furthermore, our study contributes to the generation of novel therapeutic approaches for AD and other neurodegenerative disorders. We suggest ZN014 might be potential to be further developed as a compound in AD treatment.
- TOWARD THE REMEDIES FOR EARLY DETECTION, DIAGNOSTICS AND THERAPEUTICS OF ALZHEIMER'S DISEASE (EXHIBITION) - Dec 23, 2022 - Abstract #ADPD2023ADPD_1317;
We suggest ZN014 might be potential to be further developed as a compound in AD treatment. In conclusion, F -SLOH can abrogate multiple neu ropathological abnormalities in AD mouse models, and hold outstanding therapeutic potential for prophylactic and treatment applications of AD.
- TRANSCRIPTOMIC PROFILING OF CEREBRAL ORGANOIDS REVEALS DYSREGULATED GENES IN A SUBPOPULATION OF PSEN1-MUTANT ASTROCYTES IN REGULATING MITOCHONDRIA AND LYSOSOMAL PROCESSES (EXHIBITION) - Dec 23, 2022 - Abstract #ADPD2023ADPD_1273;
Ultimately, unravelling deregulation of mitochondria and lysosomal processes in astrocytes and its effects on A? clearance will shed light on their involvement in AD progression.
- UNRAVELLING AMYLOID BETA PLAQUE PATHOLOGY ASSOCIATED LIPID PATTERNS IN GENETIC ALZHEIMER'S DISEASE MOUSE MODELS (EXHIBITION) - Dec 23, 2022 - Abstract #ADPD2023ADPD_1246;
plaque pathology. The results highlight the heterogeneous metabolism of neuronal lipid is associated with amyloid plaque polymorphism.
- TO EVALUATE THE ANTI-AMYLOIDOGENIC ACTIVITY OF NOVEL 4-PBA DERIVATIVES ON THE AMYLOID FIBRIL FORMATION, IN VITRO STUDY (EXHIBITION) - Dec 23, 2022 - Abstract #ADPD2023ADPD_1164;
The results highlight the heterogeneous metabolism of neuronal lipid is associated with amyloid plaque polymorphism. The compounds RJ1, RJ2, and RJ3 demonstrated significant neuroprotective ability thus ma king them potential candidates for the development of drugs for treating AD.
- UNDERSTANDING THE ROLE OF EXTRACELLULAR VESICLES IN THE PATHOPHYSIOLOGY OF ALZHEIMER'S DISEASE (EXHIBITION) - Dec 23, 2022 - Abstract #ADPD2023ADPD_1163;
The study highlights involvement of PrPC-expressing EVs in A? aggregation -rescue mechanism against A?o toxicity, and in AD -specific EV -mediated intercellular communication.
- CHARACTERIZATION OF AMYLOID-BETA STRAINS FROM SWEDISH AND ARCTIC ALZHEIMER'S DISEASE IN MICE (EXHIBITION) - Dec 23, 2022 - Abstract #ADPD2023ADPD_1159;
Characterizing the distinct A? aggregates involved in di fferent types of AD could lead to more targeted and effective therapeutics.
- BIOPHYSICAL MARKER FOR A? GROWTH PATHWAY VIA THE A? STRUCTURE-SPECIFIC LABEL-FREE TERAHERTZ MONITORING (EXHIBITION) - Dec 23, 2022 - Abstract #ADPD2023ADPD_1152;
aggregation dynamics in real-time and can ultimately facilitate early AD diagnosis by clearly differentiating of A? oligomer state between monomer and fibril states in a nanomolar concentration(~nm).
- Leqembi (lecanemab) / Biogen, BioArctic, Eisai, donanemab (LY3002813) / Eli Lilly
COMPARING THE DYMANICS OF AMYLOID BETA SPECIES FOR TWO DIFFERENT ALZHEIMER'S DISEASE AGENTS, DONANEMAB AND LECANEMAB, USING A QSP PLATFORM (On-Demand Oral Gallery F) - Dec 23, 2022 - Abstract #ADPD2023ADPD_1129;
species in plasma, CSF, and ISF. It is a valuable tool to explore the impact of treatments on amyloid dynamics and safety.
- SOMATOSTATIN SLOWS A? PLAQUE DEPOSITION IN AGED APPNL-F/NL-F MICE BY BLOCKING A? AGGREGATION IN A NEPRILYSIN-INDEPENDENT MANNER (On-Demand Oral Gallery G) - Dec 23, 2022 - Abstract #ADPD2023ADPD_815;
amyloid plaque formation through direct interference with A? aggregation rather than through its effects on neprilysin expression.
- EARLY DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE BY TARGETING TOXIC SOLUBLE A? OLIGOMERS (On-Demand Oral Gallery G) - Dec 23, 2022 - Abstract #ADPD2023ADPD_814;
aggregation rather than through its effects on neprilysin expression. Cyclic (aza)peptides offer novel promise for early AD diagnosis and therapy by targeting the soluble oligome rs.
- DESIGNING A NOVEL DROSOPHILA MODEL OF ALZHEIMER'S DISEASE TO STUDY ABETA PROTEOTOXICITY IN THE DIGESTIVE TRACT (On-Demand Oral Gallery E) - Dec 23, 2022 - Abstract #ADPD2023ADPD_794;
-expressing fly model can be used to study the mec hanism of A? proteotoxicity and to screen for novel therapeutic candidates to combat AD.
- IMPAIRED AUTOPHAGY AND MITOPHAGY IN APOE4 N9 MICROGLIA CELLS (On-Demand Oral Gallery D) - Dec 23, 2022 - Abstract #ADPD2023ADPD_775;
proteotoxicity and to screen for novel therapeutic candidates to combat AD. Impaired autophagy in ApoE4 and PS1 mutation N9 microglia cells.
- ALTERING BRAIN AMYLOIDOSIS BY INTRA-LINGUAL AND EXTRA-NASAL EXPOSURE OF A? AGGREGATES. (ONSITE - HALL G2) - Dec 23, 2022 - Abstract #ADPD2023ADPD_714;
Conclusions Our results show that exposing highly innervated tissues to A? seeds accelerates Alzheimer
- MICROGLIA DEFICIENT IN TREM2 MAY PROMOTE AMYLOID-BETA PLAQUE GROWTH BY RELEASING LYSOSOMAL CONTENTS DURING DIGESTIVE EXOPHAGY. (ONSITE - HALL F4+F5) - Dec 23, 2022 - Abstract #ADPD2023ADPD_599;
Our work introduces digestive exophagy as a novel mechanism by which microglia interact with A? deposits, and might shed some light into mechanisms by which TREM2 contributes to AD.
- CROSS-SEEDING OF AMYLOID-BETA BY FOOD PROTEIN AMYLOIDS (On-Demand Oral Gallery H) - Dec 23, 2022 - Abstract #ADPD2023ADPD_543;
The results suggest that food -derived amyloid is not a major risk factor f or development of A? pathology.
- CHEMICAL IMAGING OF AMYLOID AGGREGATION DYNAMICS USING ISILK (On-Demand Oral Gallery H) - Dec 23, 2022 - Abstract #ADPD2023ADPD_536;
The results bring considerable novel information about the deposition mechanism of A? and its toxic interactions with the surrounding.
- FLUORINATED LIPOSOMES MODIFIED WITH TRANSFERRIN TO TARGET THE BRAIN AND THE AMYLOID-BETA PEPTIDE: AN INNOVATIVE STRATEGY AGAINST ALZHEIMER'S DISEASE (On-Demand Oral Gallery E) - Dec 23, 2022 - Abstract #ADPD2023ADPD_503;
The developed fluorinated liposomes can be a promising nanocarrier to target the brain and prevent or treat AD. Furthermore, this formulation may result in the creation of more novel nano -fluorinated therapeutics in th e future.
- CONSEQUENCES OF ACYL CHAIN DYSHOMEOSTASIS IN ALZHEIMER'S DISEASE (ONSITE - HALL G3) - Dec 23, 2022 - Abstract #ADPD2023ADPD_361;
aggregation. Conclusions Altered acyl chain content across phospholipids in AD progression is likely to reflect functional changes in lipid content and implicate disruption of endogenous nanoparticle mediated distribution of lipids.
- NOVEL A? VARIANTS AS VASCULAR AMYLOID "SEEDING-TEMPLATE-INHIBITOR" CANDIDATES IN CEREBRAL AMYLOID ANGIOPATHY (ONSITE - HALL F1+F2+F3) - Dec 23, 2022 - Abstract #ADPD2023ADPD_293;
accumulation can be interrupted. E.g., accelerating the removal of potent "seeds" will enhance proteolytic clearance.
- AD RISK GENES AND BLOOD-BRAIN BARRIER DYSFUNCTION (ONSITE - HALL F4+F5) - Dec 23, 2022 - Abstract #ADPD2023ADPD_77;
Our findings may be relevant for therapies targetting BBB dysfunction. 1.
- A 56 KDA SDS-STABLE, SOLUBLE, NON-PLAQUE-RELATED, BRAIN-DERIVED OLIGOMER COMPRISED OFCANONICAL A?40 (ONSITE - HALL F1+F2+F3) - Dec 23, 2022 - Abstract #ADPD2023ADPD_50;
Urea and guanidium hydrochloride dissociated the 56 kDa moiety comprised of canonical A?40, indicating that the the 56 kDa moiety is an A?40 oligomer. Conclusions We conclude that aqueous brain extracts of Tg2576 mice contain a specific 56 kDa SDS-stable, non-plaque-associated, soluble oligomer comprised of canonical A?40, also known as A?*56.
- THE AMYLOID SCAFFOLD HYPOTHESIS (ONSITE - HALL F1+F2+F3) - Dec 23, 2022 - Abstract #ADPD2023ADPD_47;
These data reinforce the role of amyloid in AD and other disorders but suggest that downstream pathology induced by amyloid is incredibly complex and that important pathophysiologic changes may be mediated by other co-accumulating proteins. Indeed, perhaps rather than direct toxicity is it is the scaffolding function of amyloid which results in sequestration of numerous signaling molecules that truly drives the pathophysiologic cellular responses that lead to organ failure.
- | Journal: Stepwise Coordination-Driven Metal-Phenolic Nanoparticle as a Neuroprotection Enhancer for Alzheimer's Disease Therapy. (Pubmed Central) - Dec 22, 2022
Moreover, an intravenous injection of these nanoparticles potently improves the cognitive function in APP/PS1 mice without adverse effects. Overall, our work provides a promising approach to develop advanced nanomaterials for multi-target treatment of AD.
- | Journal: Amyloid futures in the expanding pathology of brain aging and dementia. (Pubmed Central) - Dec 20, 2022
The extensive overlap of soluble Aβ levels in controls with AD contrasts with the PET findings on fibrillar Aβ. These findings further support fibrillar Aβ as a biomarker for AD treatments and show the need for more detailed postmortem analysis of diverse soluble and insoluble Aβ aggregates in relation to PET.
- | Journal: Epigallocatechin gallate-derived carbonized polymer dots: A multifunctional scavenger targeting Alzheimer's β-amyloid plaques. (Pubmed Central) - Dec 13, 2022
Notably, E-CPDs exhibited enhanced fluorescence emission upon binding to Aβ fibrils, possessing potential as Aβ fluorescent probes. It is believed that this work would open a new horizon in the design of multifunctional carbon nanomaterials as a potent amyloid scavenger for AD theranostics.
- || Review, Journal: In Silico Studies to Predict the Role of Solvent in Guiding the Conformations of Intrinsically Disordered Peptides and Their Aggregated Protofilaments. (Pubmed Central) - Dec 13, 2022
This review discusses some of the recent findings obtained from our simulation studies on Aβ and α-synuclein monomers and small preformed Aβ aggregates. A molecular-level insight of the aggregation process with a special emphasis on the role of water in inducing the aggregation process has been provided.
- | Journal: Synthesis, single crystal characterization and anti-AD activities of a novel complex of Cu(II) with in situ formed protonated chrysin derivative ligand. (Pubmed Central) - Dec 12, 2022
The studies in silico showed that 1 had brain availability and peroral bioavailability. Taken together, compound 1, as the derivative of chrysin, might be a promising advanced lead candidate for the development of new anti-AD drugs and it may provide a useful template for studying the structure-activity relationships of biometal-coordinating drugs.
- || Review, Journal: Synthetic, Cell-Derived, Brain-Derived, and Recombinant β-Amyloid: Modelling Alzheimer's Disease for Research and Drug Development. (Pubmed Central) - Dec 12, 2022
Further, the paper discusses the causes of the reported differences in the effect of Aβ obtained from the sources mentioned above. This review points to the importance of the source of Aβ for AD modelling and could help researchers to choose the optimal way to model the Aβ-induced abnormalities.
- | Journal: The Real-Time Validation of the Effectiveness of Third-Generation Hyperbranched Poly(ɛ-lysine) Dendrons-Modified KLVFF Sequences to Bind Amyloid-β Peptides Using an Optical Waveguide Light-Mode Spectroscopy System. (Pubmed Central) - Dec 12, 2022
In this study, hyperbranched poly-L-lysine dendrons presenting sixteen KLVFF at their uppermost molecular branches were designed with the aim of providing the KLVFF sequence with a molecular scaffold able to increase its stability and of improving Aβ fibril formation inhibitory effect. These high-purity branched KLVFF were used to functionalise the surface of the metal oxide chip of the optical waveguide lightmode spectroscopy sensor showing the more specific, accurate and rapid measurement of Aβ than that detected by linear KLVFF peptides.
- Aduhelm (aducanumab) / Eisai, Biogen
HYDROXYLATED DOCOSAHEXAENOIC ACID AS AN ALTERNATIVE THERAPEUTIC APPROACH FOR ALZHEIMER DISEASE IN TERMS OF EFFICACY AND SAFETY. () - Dec 9, 2022 - Abstract #CTAD2022CTAD_454;
So far, only aducanumab (passive immunotherapy against β-amyloid peptide -Aβ-) has recently obtained accelerated approval by the FDA (Food & Drug Administration) amidst great controversy due to poor clinical evidence regarding All abstracts are embargoed until the day and time of presentation at the CTAD Conference S233 efficacy in preventing AD-related cognitive decline...This data points towards a large therapeutic window and a good safety profile for DHA-H for clinical trials in humans. COI: Victoria Llado holds an employment agreement and is a directors board member of Laminar Pharma Inc, subsidiary of Laminar Pharmaceuticals which is the company responsible for DHA-H development.
- lecanemab (BAN2401) / Biogen, BioArctic, Eisai
CHARACTERIZING THE MOLECULAR DETERMINANTS OF THE LECANEMAB PARATOPE BINDING SITE BY COMBINING IN SILICO PREDICTION AND IN VITRO FAB ANALYSIS ON AD BRAIN EXTRACTS () - Dec 9, 2022 - Abstract #CTAD2022CTAD_450;
In silico prediction of the structural details of Lecanemab provided a useful starting point that could be tested and confirmed in vitro via the expression of WT and mutant Fabs of lecanemab. The molecular determinants of the Aβ binding site as well as the antigen regions where they bind were characterized.